Gilead-backed AlloVir has filed to raise up to $100m in an offering that will support the clinical development of a treatment for viral diseases.
AlloVir, a US-based cell therapy developer backed by pharmaceutical firm Gilead Sciences, filed for a $100m initial public offering on the Nasdaq Global Market on Monday.
Founded in 2013, AlloVir is working on cell therapies generated from healthy donors that are designed to restore natural immunity in patients who suffer from T cell deficiencies and are at risk from potentially fatal viral diseases.
The company was set up by ElevateBio, a holding firm established to incubate cell and gene…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
